The company is developing antibody-oligonucleotide conjugates aimed at treating muscular dystrophy. The article frames the work as efforts to restore muscle function, illustrated by a hand/fist exercise in the lede. It reports a $100M financing to advance the program. The financing is presented as supporting the development and dispatch of these conjugates toward muscular dystrophy. Eli Lilly is identified in the article as a backer of the company.

Total raised

$100M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2019